Cocrystal Pharma, Inc. (COCP) News
Filter COCP News Items
COCP News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
COCP News Highlights
- COCP's 30 day story count now stands at 2.
- Over the past 3 days, the trend for COCP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about COCP are WASH.
Latest COCP News From Around the Web
Below are the latest news stories about COCRYSTAL PHARMA INC that investors may wish to consider to help them evaluate COCP as an investment opportunity.
Cocrystal Pharma Announces Participation in Virtual Investor EventsBOTHELL, Wash., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the participation of James Martin, co-CEO and CFO, in the following virtual investment community events: Noble Capital Markets’ J.P. Morgan Healthcare Conference Takeaways hosted by ChannelChek featuring an interview with Noble Capital Market’s managing director and senior biotechnology analyst Robert LeBoyer discussing management’s perspective on the market environment for biotechnology companies a |
Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day PodcastPhoenix, Arizona--(Newsfile Corp. - January 23, 2023) - The Stock Day Podcast welcomed Cocrystal Pharma, Inc. (NASDAQ: COCP) ("Cocrystal," "Cocrystal Pharma" or "the Company"), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to crea |
Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza ABOTHELL, Wash., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces highly favorable safety and tolerability results for its orally administered replication inhibitor CC-42344 in its Phase 1 study. CC-42344 is a broad-spectrum antiviral for the treatment of pandemic and seasonal influenza A with a novel mechanism of action. The randomized, double-controlled Phase 1 study was conducted in Australia to evaluate the safety, tolerability and pharmacokinetics (PK) of CC- |
Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022Affirms plans to report topline Phase 1 results in 2022 and to initiate Phase 2a influenza human challenge trial in 2023 BOTHELL, Wash., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that progress with CC-42344 for the treatment of pandemic and seasonal influenza A from its Phase 1 study was presented today at the World Antiviral Congress 2022 underway in San Diego. The presentation, “Novel Broad-Spectrum Influenza A PB2 Inhibitor: Clinical Update,” was delive |
Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza ACocrystal Pharma Inc (NASDAQ: COCP) announced that CC-42344 demonstrated a favorable safety profile in the single-ascending and multiple-ascending dose portions of the ongoing Phase 1 study. CC-42344 is a broad-spectrum oral antiviral for pandemic and seasonal influenza A. The randomized, double-controlled, dose-escalating Phase 1 study in Australia was designed to assess the safety, tolerability, and pharmacokinetics (PK) of orally administered CC-42344 in healthy adults. Related: Cocrystal Pha |
Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza ABOTHELL, Wash., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) today announced that CC-42344 demonstrated a favorable safety profile in both the single-ascending dose and the multiple-ascending dose portions of the ongoing Phase 1 study. CC-42344 is a broad-spectrum oral antiviral for the treatment of pandemic and seasonal influenza A with a novel mechanism of action. “We are encouraged by the clean safety profile observed with all dose levels in both the single-ascendin |
Noble Financial Sticks to Its Buy Rating for Cocrystal Pharma (COCP)Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Cocrystal Pharma (COCP - Research Report) today and set a price target of $10.00. The company's shares closed yesterday at $3.03.LeBoyer covers the Healthcare sector, focusing on stocks such as PDS Biotechnology, Ayala Pharmaceuticals, and Ocugen. According to TipRanks, LeBoyer has an average return of 3.6% and a 30.87% success rate on recommended stocks. Cocrystal Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $26.00, which is a 758.09% upside from current levels. In a report released on November 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $42.00 price target. |
COCP: UPDATE: Cocrystal Pharma releases 2022 3rd quarter results and provides an update on the current pipeline programs.By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT Cocrystal Pharma (NASDAQ:COCP) reported 2022 3rd quarter results on November 14, 2022. General & Administrative expenses were $1.8 million and Research & Development expenses came in at $3.9 million for the quarter which was above our expectations. R&D spending is being ramped up for the influenza Phase 1 trial and the |
Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development ProgramsCompleted enrollment in the Phase 1 study with novel, broad-spectrum antiviral PB2 candidate CC-42344 for the treatment of pandemic and seasonal influenza A; remains on track to report topline results in 2022Announced oral presentation of CC-42344 Phase 1 influenza A data at the World Antiviral Congress 2022 being held in DecemberSelected novel antiviral candidate CDI-988 for clinical development as an oral treatment for SARS-CoV-2 with Phase 1 study expected to begin in the first quarter of 202 |
Analysts Are Bullish on Top Healthcare Stocks: Cocrystal Pharma (COCP), IGM Biosciences (IGMS)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cocrystal Pharma (COCP – Research Report), IGM Biosciences (IGMS – Research Report) and Cidara Therapeutics (CDTX – Research Report) with bullish sentiments. Cocrystal Pharma (COCP) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cocrystal Pharma, with a price target of $42.00. The company's shares closed last Friday at $2.39, close to its 52-week low of $2.05. According to TipRanks.com, Selvaraju has 0 stars on 0-5 stars ranking scale with an average return of -22.7% and a 22.6% success rate. |